gamma-amino-beta-hydroxybutyric acid
Small moleculeexperimental
γ-Amino-β-hydroxybutyric acid (GABOB), also known as β-hydroxy-γ-aminobutyric acid (β-hydroxy-GABA), sold under the brand name Gamibetal among others, is an anticonvulsant which is used for the treatment of epilepsy in Europe, Japan, and Mexico. It is a GABA analogue, or an analogue of the neurotransmitter γ-aminobutyric acid (GABA), and has been found to be an endogenous metabolite of GABA. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2018 (NCT03721991)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Loading structure…
SMILES
NCC(O)CC(=O)O- Mol. weight
- 119.12 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaΓ-Amino-β-hydroxybutyric acid ↗
- ChEMBLCHEMBL93515 ↗
- WikipediaGamma-Amino-beta-hydroxybutyric acid ↗
Also known as
- 3-hydroxy-gaba
- alpha-hydroxy-gaba
- aminohydroxybutyric acid
- aminohydroxybutyric acid
- beta-hydroxy-gaba
- buxamine
- gabob
- gabomade
- gaboril
- gamibetal
- gamma-amino-beta-hydroxybutyric acid
- gamma-amino-beta-hydroxybutyric acid
- gamma-amino-beta-hydroxybutyric acid
- gamma-amino-beta-hydroxybutyric acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03721991 | N/A | Oct 10, 2018 | Juvenile Diabetes Research Foundation, Steno Diabetes Center Copenhagen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Steno Diabetes Center Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1